Global Urinalysis Test Market

1 INTRODUCTION OF GLOBAL URINALYSIS TEST MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL URINALYSIS TEST MARKET OUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL URINALYSIS TEST MARKET, BY PRODUCT TYPE
5.1 Consumables
5.1.1 Dipsticks
5.1.2 Reagents and disposables
5.2 Instruments
5.2.1 Biochemical urine analyzers
5.2.1.1 Automated biochemical urine analyzers
5.2.1.2 Semi-automated biochemical urine analyzers
5.2.2 Automated urine sediment analyzers and
5.2.3 Point-of-care devices

6 GLOBAL URINALYSIS TEST MARKET, BY TEST TYPE
6.1 Biochemical urinalysis
6.2 Sediment urinalysis
6.2.1 Microscopic urinalysis
6.2.2 Flow cytometric urinalysis

7 GLOBAL URINALYSIS TEST MARKET, BY APPLICATION
7.1 Disease diagnosis
7.1.1 Urinary tract infections
7.1.2 Kidney diseases
7.1.3 Diabetes
7.1.4 Liver diseases
7.1.5 Others
7.2 Pregnancy Tests

8 GLOBAL URINALYSIS TEST MARKET, BY GEOGRAPHY
8.1 Overview
8.2 North America Regional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 Europe Regional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia Pacific Regional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin America Regional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the World Regional Market Estimates and Forecasts, 2012 â€" 2025

9 GLOBAL URINALYSIS TEST MARKET COMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES
10.1 Siemens AG
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments

10.2 F. Hoffmann-LA Roche Ltd.
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments

10.3 Danaher Corporation
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments

10.4 Sysmex Corporation
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments

10.5 Arkray Inc.
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments

10.6 Acon Laboratories Inc.
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments

10.7 Bio-Rad Laboratories Inc.
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments

10.8 77 ElektronikaKft.
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments

10.9 Shenzhen Mindray Bio-Medical Electronics Co.
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Developments

10.10 URIT Medical
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Developments

10.11 Erba Mannheim
10.11.1 Overview
10.11.2 Financial Performance
10.11.3 Product Outlook
10.11.4 Key Developments

10.12 Trinity Biotech
10.12.1 Overview
10.12.2 Financial Performance
10.12.3 Product Outlook
10.12.4 Key Developments

10.13 BioMaxima S.A.
10.13.1 Overview
10.13.2 Financial Performance
10.13.3 Product Outlook
10.13.4 Key Developments

10.14 Accurex
10.14.1 Overview
10.14.2 Financial Performance
10.14.3 Product Outlook
10.14.4 Key Developments

10.15 Quantimetrix
10.15.1 Overview
10.15.2 Financial Performance
10.15.3 Product Outlook
10.15.4 Key Developments

11 Appendix
11.1 Related Reports